Skip to main content

Table 4 Prescribed SGLT2 and GLP-1 medications for patients with diabetes mellitus and cardiovascular risk

From: Adherence of physicians to evidence-based management guidelines for treating type 2 diabetes and atherosclerotic cardiovascular disease in Ajman, United Arab Emirates

SGLT2 (n = 109) F % GLP-1 (n = 47) F %
Dapagliflozin 21 19.2 Dulaglutide 11 23.4
Dapaglifloxin 5 mg/ metformin 500 mg 2 18 Insulin degludec 2 4.3
Empagliflozin 83 76.1 Insulin degludec 5 10.6
Empagliflozin/metformin n HCL 12.5/1000 mg 3 2.8 Insulin glargine 4 8.5
Liragluide (Victoza) 16 34.04
Lixisenatide 5 10.6
Tresiba 4 8.5
  1. Abbreviations: F Frequency, GLP-1 Glucagon-like peptide 1 agonist, SGLT2 Sodium-glucose cotransporter 2 inhibitor